PHARMACEUTICAL COMPOSITION COMPRISING AN APL PEPTIDE

The invention relates to a pharmaceutical composition comprising the APL peptide of SEQ ID No. 1, the sodium acetate buffer with a pH of 3.9-4.7, and at least one stabilising sugar selected from saccharose and trehalose. This pharmaceutical composition is useful for the treatment of inflammatory dis...

Full description

Saved in:
Bibliographic Details
Main Authors DOMINGUEZ HORTA, MARIA DEL CARMEN, LOPEZ ABAD, CRUZ MATILDE, BESADA PEREZ, VLADIMIR ARMANDO, GONZALEZ LOPEZ, LUIS JAVIER
Format Patent
LanguageEnglish
French
Published 04.07.2019
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates to a pharmaceutical composition comprising the APL peptide of SEQ ID No. 1, the sodium acetate buffer with a pH of 3.9-4.7, and at least one stabilising sugar selected from saccharose and trehalose. This pharmaceutical composition is useful for the treatment of inflammatory diseases associated with an increase of neutrophils or protein citrullination. These inflammatory diseases include rheumatoid arthritis (RA), juvenile chronic arthritis (JCA), ankylosing spondylitis (AS), Alzheimer's disease and hepatic or pulmonary fibrosis. The invention also relates to a method for the treatment of these diseases by administration of a therapeutically effective dose of the pharmaceutical composition of the APL peptide of SEQ ID No. 1. L'invention concerne une composition pharmaceutique qui comprend le peptide type APL identifé comme SEQ ID No. 1, le tampon acétate de sodium à pH compris entre 3,9 et 4,7; et au moins un sucre stabilisant sélectionné parmi le saccharose et le tréhalose. Cette composition pharmaceutique est utile dans le traitement des maladies inflammatoires en rapport avec une augmentation des neutrophiles ou de la citrullination de protéines. Parmi ces maladies inflammatoires, on compte la polyarthrite rhumatoïde (AR), l'arthrite chronique juvénile (AIJ), la spondylarthrite ankylosante (EA), la maladie d'Alzheimer, et la fibrose hépatique ou pulmonaire. L'invention concerne également un procédé pour le traitement de ces maladies, par administration d'une quantité thérapeutiquement efficace de la composition pharmaceutique du peptide type APL identifié comme SEQ ID No.1.
Bibliography:Application Number: CA20183086280